Base de dados : LILACS
Pesquisa : D20.215.894.200 [Categoria DeCS]
Referências encontradas : 34 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 34 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: lil-748783
Autor: Casacó Parada, Ángel R; Fernández Lorente, Aymara.
Título: Efectos del bloqueo del sistema EGF/EGFR sobre la cicatrización de las heridas en pacientes oncológicos / Effects of the blockade of EGF/EGFR system on wound healing cancer patients
Fonte: Rev. cuba. farm;48(4), oct.-dic. 2014.
Idioma: es.
Resumo: La administración de drogas que bloquean el sistema del factor de crecimiento epidérmico y su receptor ha demostrado efectos beneficiosos en pacientes con tumores sólidos de origen epitelial. Cada día resulta más frecuente el uso de múltiples modalidades terapéuticas para combatir estos tumores, las cuales incluyen la asociación de agentes blanco y cirugía. Los agentes que actúan sobre dicho sistema pudieran causar trastornos de la cicatrización al bloquear vías del sistema que también intervienen en la cicatrización de las heridas. El objetivo de este artículo es revisar y comentar acerca del conocimiento de la relación entre el uso de las drogas anti-EGF/EGFR y los trastornos en la cicatrización de las heridas. La búsqueda bibliográfica se realizó en PubMed y Google (solo en español e inglés) y se tuvo en cuenta cualquier publicación encontrada hasta enero del 2014. Se incluyeron los anticuerpos monoclonales cetuximab, panitumumab y nimotuzumab; las pequeñas moléculas erlotinib y gefitinib y las vacunas terapéuticas contra el cáncer CIMAvax EGF y HER-1. Se hace especial énfasis en los biofarmacéuticos nimotuzumab, CIMAvax EGF y HER-1; producidos en el Centro de Inmunología Molecular, La Habana, Cuba, debido a su amplio uso en Cuba y otros países de América Latina. No se encontraron evidencias de relación entre el uso de estos productos y la aparición de trastornos en la cicatrización de las heridas. Dado que los tratamientos anti-EGF/EGFR también inhiben la proliferación celular que induce el drenaje de las heridas y la migración celular inducida por las radiaciones, se sugiere que el tratamiento anti-EGF/EGFR no debe suspenderse, ni antes ni después de la cirugía y sus posibles efectos deben ser vigilados. Obviamente, se necesitan ulteriores investigaciones por parte de los farmacólogos no clínicos y clínicos, oncólogos clínicos y cirujanos oncológicos para entender mejor los procesos fisiopatológicos de cicatrización en los cánceres de origen epitelial(AU)

The use of blocking drugs for epidermal growth factor and its receptor system has shown beneficial effects in patients with solid tumors of epithelial origin. It is increasingly common to use a multi-modal treatment approach towards solid tumors, often including the association of target agents and surgical resection. Some target agents can impair wound healing or cause increasing risk of perioperative complications if they block system pathways that may intervene in wound healing. The objective of this paper was to review and comment on the existing knowledge about the relationship between the use of anti-EGF/EGFR drugs and the disorders in wound healing. Citations from PubMed and Google (English and Spanish languages only) regardless of the date of publication were reviewed to identify potentially useful articles until January 2014. Monoclonal antibodies cetuximab, panitumumab, nimotuzumab; the small molecules erlotinib and gefitinib, and the therapeutic cancer vaccines called CIMAvax EGF and HER-1. Special emphasis was made on biopharmaceuticals nimotuzumab, CIMAvax EGF and HER-1, all of them produced at the Center of Molecular Immunology, Havana, Cuba, because of their extensive use in Cuba and many Latin-American countries. No evidence of association between the use of these products and the occurrence of complications in wound healing was found. Given that the anti-EGF/EGFR treatments also inhibit the tumor cell proliferation that wound drainage induces and the radiation-induced cell migration, it is suggested that that the administration of this kind of drugs should be kept before and after the surgery and consequently, its possible effects must be under surveillance. Obviously, non-clinical and clinical pharmacologists, clinical oncologists and surgeons need further researches for better understanding the pathophysiological wound healing processes in epithelial cancers(AU)
Descritores: Cicatrização
Vacinas Anticâncer/uso terapêutico
Anticorpos Monoclonais/imunologia
Neoplasias/cirurgia
-Cuba
Limites: Humanos
Masculino
Feminino
Responsável: CU1.1 - Biblioteca Médica Nacional


  2 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Colvero, Luciana de Almeida
Texto completo
Id: lil-731283
Autor: Campelo, Lany Leide de Castro Rocha; Costa, Sarah Maria Esequiel; Colvero, Luciana de Almeida.
Título: Difficulties of familes in caring for children and adolescents with mental disorders: an integrative review / Dificultades de las familias en la atención a niños y jóvenes con trastorno mental: una revisión integral / Dificuldades das famílias no cuidado à criança e ao adolescente com transtorno mental: uma revisão integrativa
Fonte: Rev. Esc. Enferm. USP;48(spe):192-198, 08/2014. tab.
Idioma: en.
Resumo: Objective To identify the difficulties of families with children and/or adolescents with mental disorder. Method This is an integrative review. In December 2013, an electronic search was performed on Latin American Caribbean Literature on Health Sciences databases (LILACS) and on Electronic Medicus Index of the National Library of Medicine (MEDLINE) indexed in the Health Virtual Library (BVS) using a combination of descriptors and boolean operators as follows: mental disorders and child or adolescent and caregivers and/not health staff. Results 557 studies were identified, of which 15 were selected for this study. The findings indicated difficulties related to the care for or to interaction with children/adolescents with mental disorder. Conclusion The studies revealed difficulties related to everyday practices of care and feelings expressed during care practices, as well as in relationships with children or adolescents with mental disorder.

 .

Objetivo Identificar las dificultades de las familias con niños y/o adolescentes con desórdenes mentales. Método Se trata de una revisión integradora. Una búsqueda electrónica se realizó en diciembre de 2013, en la base de datos de la literatura caribeña Latinoamericano de Ciencias de la Salud (LILACS) y en el Índice de Electronic Medicus de la Biblioteca Nacional de Medicina (MEDLINE) indexados en la Biblioteca Virtual en Salud (BVS), utilizando combinación de descriptores y operadores booleanos transtornos mentales and niño and adolescentes and cuidadores and/not personal de salud. Resultados Se identificaron 557 estudios, de los cuales 15 fueron considerados para este estudio. Los hallazgos indican dificultades relacionadas con la atención o estar con los niños o adolescentes con trastornos mentales. Conclusión Se evidenciaron las dificultades relacionadas con las prácticas cotidianas y con los sentimientos durante la atención de quien vive con un niño o adolescente con trastornos mentales.
 .

Objetivo Identificar as dificuldades das famílias de crianças ou adolescentes com transtornos mentais. Método Trata-se de uma revisão integrativa realizada nas bases de dados da Literatura Latino-Americana do Caribe em Ciências da Saúde (LILACS) e no Index Medicus Eletrônico da National Library of Medicine (MEDLINE) indexadas na Biblioteca Virtual em Saúde (BVS) utilizando a combinação dos descritores e operadores booleanos transtornos mentais and criança or adolescente and cuidadores and/not pessoal de saúde, em dezembro de 2013. Resultados Foram identificados 557 estudos, dos quais 15 foram selecionados para este estudo. Os achados evidenciaram dificuldades relacionadas ao cuidado ou convívio com crianças ou adolescentes com transtorno mental. Conclusão Foram evidenciadas dificuldades relacionadas às práticas cotidianas e aos sentimentos manifestos durante o convívio e o cuidado de crianças ou adolescentes com transtornos mentais.
 .
Descritores: Carcinoma Hepatocelular/imunologia
Antígenos de Histocompatibilidade Classe I/metabolismo
Neoplasias Hepáticas/imunologia
-Vacinas Anticâncer/imunologia
Vacinas Anticâncer/farmacologia
Carcinoma Hepatocelular/terapia
Imuno-Histoquímica
Neoplasias Hepáticas/terapia
Linfócitos T Citotóxicos/imunologia
Células Tumorais Cultivadas
Limites: Humanos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  3 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: biblio-1002631
Autor: Columbié Regüeiferos, Justa Carmen; Rosales Calas, Mireysis; Torres Puentes, Sorelis; Veranes García, Marelis; Quintero Salcedo, Sahily.
Título: Uso de la vacuna CIMAvax-EGF® como práctica médica habitual / Use of the vaccine CIMAvax-EGF® as habitual medical practice
Fonte: Medisan;23(2), mar.-abr. 2019. tab, graf.
Idioma: es.
Resumo: Se realizó un estudio descriptivo y longitudinal de 58 pacientes con cáncer de pulmón de células no pequeñas, atendidos en la consulta de Sombras Pulmonares correspondiente al Servicio de Neumología del Hospital General Docente Dr Juan Bruno Zayas Alfonso de Santiago de Cuba, desde enero del 2013 hasta igual mes del 2018, quienes eran tratados con CIMAvax-EGF® como práctica médica habitual, con vistas a determinar las características clinicoepidemiológicas de estos. En la serie primaron el sexo masculino y las edades de 60 a 79 años; asimismo, resultaron más frecuentes la etapa IV de la enfermedad y el adenocarcinoma como variedad histológica. Con el uso de la vacuna la mayoría de los pacientes presentaron una supervivencia de 12,9 meses y una respuesta terapéutica de enfermedad no progresora

A descriptive and longitudinal study of 58 patients with lung cancer of non small cells, assisted in the service of Lung Shades corresponding to the Pneumology Service of Dr Juan Bruno Zayas Alfonso Teaching General Hospital was carried out in Santiago de Cuba, from January, 2013 to the same month of 2018, who were treated with CIMAvax-EGF® as habitual medical practice, with the aim of determining the clinical and epidemiological characteristics of them. The male sex and ages from 60 to 79 years prevailed in the series; also, stage IV of the disease and the adenocarcinoma as histological variety were more frequent. With the use of the vaccine most of the patients presented a survival of 12.9 months and a therapeutic response of the non progressive disease
Descritores: Adenocarcinoma
Carcinoma Pulmonar de Células não Pequenas/epidemiologia
Vacinas Anticâncer/uso terapêutico
Neoplasias Pulmonares/terapia
-Atenção Secundária à Saúde
Epidemiologia Descritiva
Estudos Longitudinais
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Artigo Clássico
Responsável: CU418.1 - Centro Provincial de Información de Ciencias Médicas de Santiago de Cuba


  4 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: lil-769438
Autor: Sosa, Odalis Ricardo; González Portales, Yaneisy; Ramos Ferro, Marlen; Battles Zamora, Sureimys; Díaz Hernández, Pablo; Ortega Peguero, Mercedes; González Díaz, Yanet.
Título: Experiencia en enfermería, ensayo clínico y atención a pacientes con cáncer de pulmón / Experience in nursing, clinical assay and care of patients with lung cancer
Fonte: Rev. cuba. invest. bioméd;34(2):136-144, abr.-jun. 2015. ilus, tab.
Idioma: es.
Resumo: INTRODUCCIÓN: los ensayos clínicos con nuevas sustancias, como anticuerpos y vacunas han tenido un incremento debido a la necesidad de encontrar nuevas terapéuticas para el tratamiento del cáncer. En la aplicación del tratamiento el éxito depende del buen desempeño profesional, el nivel de preparación y capacitación que tenga el personal de enfermería, como parte del equipo de investigación al ejecutar un rol importante. OBJETIVO: evaluar la experiencia del personal de enfermería en este ensayo relacionado con la atención a pacientes con cáncer de pulmón. MÉTODOS: se realizó un estudio descriptivo con una revisión bibliográfica sobre el actuar, y la experiencia de enfermería en el ensayo clínico. Se evaluó la seguridad de CIMAvax®- EGF en pacientes avanzados con tumores del pulmón, de células no pequeñas y tratados en la asistencia primaria de salud. Para ello se realizó un análisis documental de la buena práctica clínica, y los protocolos de estudios sobre el tema. RESULTADOS: fueron incluidos 11 pacientes. El promedio de diagnóstico y tratamiento de pacientes, con cáncer de pulmón estuvo en 23 y 14 meses al respecto. CONCLUSIONES: enfermero (a) en su desempeño debe tener dominio del protocolo en su totalidad sobre el producto, propiedades farmacéuticas y dosis a administrar. Además, identificar las reacciones adversas que pueden presentarse y las medidas a tomar para de esta forma lograr evaluar la efectividad del nuevo producto en investigación y mitigar cualquier riesgo que influya en la calidad y excelencia de nuestros servicios de salud.

INTRODUCTION: an increase in clinical assays of new substances, such as antibodies and vaccines, has taken place in response to the need to find new cancer therapies. Success in the application of treatment depends on the good professional performance, background and training of nursing personnel, for they play an important role as research team members. OBJECTIVE: evaluate the experience of nursing personnel in an assay about the care of patients with lung cancer. METHODS: a descriptive study was conducted based on a bibliographic review of the role and experience of nurses in the clinical assay performed. The safety of CIMAvax®- EGF was evaluated in patients with advanced non-small-cell lung tumors treated at primary health care services. For this purpose a document analysis was performed about good clinical practice and study protocols about the subject. RESULTS: eleven patients were included. Average diagnosis and treatment of patients with lung cancer was 23 and 14 months, respectively. CONCLUSIONS: nurses should be thoroughly aware of the entire protocol, particularly the product, its pharmaceutical properties and the dose to administer. They should also be able to identify the potential adverse reactions and the measures to take to assess the effectiveness of the new product under research, as well as mitigate any risk affecting the quality and excellence of our health services.
Descritores: Vacinas Anticâncer/uso terapêutico
Papel do Profissional de Enfermagem
Ensaio Clínico Pragmático
Neoplasias Pulmonares/terapia
Limites: Humanos
Responsável: CU1.1 - Biblioteca Médica Nacional


  5 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-797890
Autor: Mai, TJ; Ma, R; Li, Z; Bi, SC.
Título: Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;49(11):e5620, 2016. graf.
Idioma: en.
Resumo: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a negative regulator of T cell activation, which competes with CD28 for B7.1/B7.2 binding, and which has a greater affinity. Fusion of specific antigens to extracellular domain of CTLA4 represents a promising approach to increase the immunogenicity of DNA vaccines. In this study, we evaluated this interesting approach for CTLA4 enhancement on prostate stem cell antigen (PSCA)-specific immune responses and its anti-tumor effects in a prostate cancer mouse model. Consequently, we constructed a DNA vaccine containing the PSCA and the CTLA-4 gene. Vaccination with the CTLA4-fused DNA not only induced a much higher level of anti-PSCA antibody, but also increased PSCA-specific T cell response in mice. To evaluate the anti-tumor efficacy of the plasmids, murine models with PSCA-expressing tumors were generated. After injection of the tumor-bearing mouse model, the plasmid carrying the CTLA4 and PSCA fusion gene showed stronger inhibition of tumor growth than the plasmid expressing PSCA alone. These observations emphasize the potential of the CTLA4-fused DNA vaccine, which could represent a promising approach for tumor immunotherapy.
Descritores: Antígenos de Neoplasias/uso terapêutico
Vacinas Anticâncer/uso terapêutico
Antígeno CTLA-4/uso terapêutico
Proteínas de Neoplasias/uso terapêutico
Plasmídeos/uso terapêutico
Neoplasias da Próstata/terapia
Vacinas de DNA/uso terapêutico
-Antígenos de Neoplasias/imunologia
Antígenos de Neoplasias/metabolismo
Vacinas Anticâncer/imunologia
Antígeno CTLA-4/genética
Antígeno CTLA-4/imunologia
Modelos Animais de Doenças
Proteínas Ligadas por GPI/imunologia
Proteínas Ligadas por GPI/metabolismo
Proteínas Ligadas por GPI/uso terapêutico
Proteínas de Neoplasias/imunologia
Proteínas de Neoplasias/metabolismo
Plasmídeos/genética
Neoplasias da Próstata/imunologia
Proteínas Recombinantes de Fusão/uso terapêutico
Vacinas de DNA/genética
Limites: Animais
Masculino
Camundongos
Responsável: BR1.1 - BIREME


  6 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Mill, José Geraldo
Szwarcwald, Célia Landmann
Texto completo
Id: lil-776704
Autor: Mill, José Geraldo; Rodrigues, Sérgio Lamêgo; Baldo, Marcelo Perim; Malta, Deborah Carvalho; Szwarcwald, Celia Landmann.
Título: Estudo de validação das equações de Tanaka e de Kawasaki para estimar a excreção diária de sódio através da coleta da urina casual / Validation study of the Tanaka and Kawasaki equations to estimate the daily sodium excretion by a spot urine sample
Fonte: Rev. bras. epidemiol;18(supl.2):224-237, Out.-Dez. 2015. tab, graf.
Idioma: en.
Resumo: RESUMO: Objetivo: Validar as fórmulas de Tanaka e Kawasaki para cálculo do consumo de sal pela relação sódio/creatinina na urina casual. Métodos: Foram estudados 272 adultos (20 - 69 anos, 52,6% de mulheres) com coleta urinária de 24 h e duas coletas casuais no mesmo dia (em jejum - casual 1 - e fora do jejum - casual 2). Antropometria, pressão arterial e coleta de sangue foram obtidos no mesmo dia. A concordância entre o consumo de sal estimado pela urina de 24 h e pela urina casual foi feita por Pearson (r) e Bland & Altman. Resultados: O consumo médio de sal medido pela urina de 24 h foi de 10,4 ± 5,3 g/dia. A correlação entre a excreção de sódio na urina de 24 h e a estimada pela urina casual 1 ou 2, respectivamente, foi apenas moderada, tanto por Tanaka (r = 0,51 e r = 0,55; p < 0,001) como por Kawasaki (r = 0,52 e r = 0,54; p < 0,001). Observa-se subestimação crescente dos valores estimados em relação ao medido com o aumento do consumo de sal pela fórmula de Tanaka e, ao contrário, superestimação ao usar a fórmula de Kawasaki. As fórmulas estimam adequadamente o consumo diário de sal (diferença entre sal medido e estimado de, no máximo, 1 g/dia) somente com consumo entre 9 - 12 g/dia (Tanaka) e 12 - 18 g/dia (Kawasaki). Conclusão: A coleta de urina casual estima adequadamente o consumo de sal apenas nos indivíduos próximos à média populacional.

ABSTRACT: Objective: To validate Tanaka and Kawasaki's formulas to calculate the salt intake by the sodium/creatinine ratio in spot of urine. Methods: Two hundred and seventy two adults (20 - 69 years old; 52.6% women) with 24 h urine collection and two urinary spots collected on the same day (while fasting - spot 1 - or not fasting - spot 2). Anthropometry, blood pressure and fasting blood were measured on the same day. The analysis of agreement between salt consumption measured in the 24 h urine test and urinary spots were determined by the Pearson's correlation (r) and the Bland & Altman method. Results: The mean salt consumption measured by the 24 h sodium excretion was 10.4 ± 5.3 g/day. The correlation between the measured 24 h sodium excretion and the estimation based on spots 1 and 2, respectively, was only moderated according to Tanaka (r = 0.51 and r = 0.55; p < 0.001) and to Kawasaki (r = 0.52 and r = 0.54; p < 0.001). We observed an increasing underestimation of salt consumption by Tanaka to increasing salt consumption and conversely, an overestimation of consumption by the Kawasaki formula. The estimation of salt consumption (difference between measured and calculated salt consumption lower than 1 g/day) was adequate only when the consumption was between 9 - 12 g/day (Tanaka) and 12 - 18 g/day (Kawasaki). Conclusion: Spot urine sampling is adequate to estimate salt consumption only among individuals with an actual consumption near the population mean.
Descritores: Vacinas Anticâncer/administração & dosagem
/imunologia
CHEMOKINE CCLABOMASUM/imunologia
Composição de Medicamentos
-Linhagem Celular Tumoral
Microambiente Tumoral
Limites: Animais
Camundongos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  7 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-755239
Autor: Segatto, Teresa Cristina Vieira.
Título: A vacinação contra o HPV, a intersetorialidade como processo do alcance da vacinação das adolescentes no Distrito Federal / Vaccination against HPV, the intersectionality as a process
Fonte: Comun. ciênc. saúde;23(4):295-296, set.-dez. 2012.
Idioma: pt.
Resumo: A vacinação contra HPV em meninas entrou no rol das ações de prevenção primária visando a médio e longo prazo reduzir a incidência do câncer do colo do útero no DF.
Descritores: Vacinas Anticâncer
Condiloma Acuminado/prevenção & controle
Vacinas contra Papillomavirus
Saúde Pública
-Adolescente
Prevenção Primária
Limites: Humanos
Feminino
Adolescente
Tipo de Publ: Editorial
Responsável: BR599.1 - Coordenação Geral de Documentação e Informação (CGDI)


  8 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-751317
Autor: Svidnicki, Paulo Vinicius; Leite, Nayara Carvalho; Vicari, Marcelo Ricardo; Almeida, Mara Cristina de; Artoni, Roberto Ferreira; Favero, Giovani Marino; Grassiolli, Sabrina; Nogaroto, Viviane.
Título: Swim training and the genetic expression of adipokines in monosodium glutamate-treated obese rats
Fonte: Arch. endocrinol. metab. (Online);59(3):210-214, 06/2015. tab, graf.
Idioma: en.
Resumo: Objective The aim of this study was to evaluate the genetic expression of adipokines in the adipocytes of monosodium glutamate (MSG)-treated obese rats submitted to physical activity.Materials and methods Obesity was induced by neonatal MSG administration. Exercised rats (MSG and control) were subjected to swim training for 30 min for 10 weeks, whereas their respective controls remained sedentary. Total RNA was obtained from sections of the mesenteric adipose tissue of the rats. mRNA levels of adiponectin (Adipoq), tumor necrosis factor alpha (Tnf), peroxisome proliferator-activated receptor alpha (Ppara), and peroxisome proliferator-activated receptor gamma (Pparg) adipokines were quantified by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).Results In the exercise-trained control group, the expression of Adipoq increased compared to the sedentary control, which was not observed in the MSG-obese rats. Increased levels of Tnf in MSG-obese rats were not reversed by the swim training. The expression of Ppara was higher in sedentary MSG-obese rats compared to the sedentary control. Swimming increased this adipokine expression in the exercise-trained control rats compared to the sedentary ones. mRNA levels of Pparg were higher in the sedentary MSG-rats compared to the sedentary control; however, the exercise did not influenced its expression in the groups analyzed.Conclusions In conclusion, regular physical activity was not capable to correct the expression of proinflammatory adipokines in MSG-obese rat adipocytes.
Descritores: Adjuvantes Imunológicos
Mimetismo Molecular/imunologia
Fatores de Necrose Tumoral
Vacinas Sintéticas/imunologia
Vacinas/química
Vacinas/imunologia
-Adjuvantes Imunológicos/química
/imunologia
ANTIGENS, CDABRUPTIO PLACENTAE/imunologia
/química
CDABRUPTIO PLACENTAE LIGAND/química
/metabolismo
CDABRUPTIO PLACENTAE LIGAND/metabolismo
Vacinas Anticâncer/química
Vacinas Anticâncer/imunologia
Vetores Genéticos/genética
Vetores Genéticos/imunologia
Imunoterapia
Ligantes
Lentivirus/genética
Lentivirus/imunologia
Macaca mulatta
Neoplasias/imunologia
Neoplasias/terapia
Multimerização Proteica
Ligante Indutor de Apoptose Relacionado a TNF/química
Receptores Toll-Like/agonistas
Fatores de Necrose Tumoral/química
Vacinas Sintéticas/química
Proteínas da Matriz Viral/imunologia
Limites: Animais
Humanos
Tipo de Publ: Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Revisão
Responsável: BR1.1 - BIREME


  9 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-700405
Autor: Salazar-Onfray, Flavio; Pereda, Cristián; Reyes, Diego; López, Mercedes N.
Título: TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
Fonte: Biol. Res;46(4):431-440, 2013. ilus, graf, tab.
Idioma: en.
Resumo: Here we summarize 10 years of effort in the development of a biomedical innovation with global projections. This innovation consists of a novel method for the production of therapeutic dendritic-like cells called Tumor Antigen Presenting Cells (TAPCells®). TAPCells-based immunotherapy was tested in more than 120 stage III and IV melanoma patients and 20 castration-resistant prostate cancer patients in a series of phase I and I/II clinical trials. TAPCells vaccines induced T cell-mediated memory immune responses that correlated with increased survival in melanoma patients and prolonged prostate-specific antigen doubling time in prostate cancer patients. Importantly, more than 60% of tested patients showed a Delayed Type Hypersensitivity (DTH) reaction against the lysates, indicating the development of anti-tumor immunological memory that correlates with clinical benefits. The in vitro analysis of the lysate mix showed that it contains damage-associated molecular patterns such as HMBG-1 protein which are capable to improve, through Toll-like receptor-4, maturation and antigen cross-presentation of the dendritic cells (DC). In fact, a Toll-like receptor-4 polymorphism correlates with patient clinical outcomes. Moreover, Concholepas concholepas hemocyanin (CCH) used as adjuvant proved to be safe and capable of enhancing the immunological response. Furthermore, we observed that DC vaccination resulted in a three-fold increase of T helper-1 lymphocytes releasing IFN-γ and a two-fold increase of T helper-17 lymphocytes capable of producing IL-17 in DTH+ with respect to DTH- patients. Important steps have been accomplished for TAPCells technology transfer, including patenting, packaging and technology assessment. Altogether, our results indicate that TAPCells vaccines constitute an exceptional Chilean national innovation of international value.
Descritores: Antígenos de Neoplasias/imunologia
Vacinas Anticâncer/administração & dosagem
Células Dendríticas/imunologia
Melanoma/terapia
Neoplasias da Próstata/terapia
Neoplasias Cutâneas/terapia
-Chile
Extratos Celulares/imunologia
Extratos Celulares/uso terapêutico
Melanoma/imunologia
Estadiamento de Neoplasias
Neoplasias da Próstata/imunologia
Neoplasias Cutâneas/imunologia
Resultado do Tratamento
/imunologia
TOLL-LIKE RECEPTOR ABBREVIATIONS AS TOPIC/imunologia
Limites: Feminino
Humanos
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Revisão
Responsável: CL1.1 - Biblioteca Central


  10 / 34 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Texto completo
Id: lil-659889
Autor: Lage Dávila, Agustín; Crombet Ramos, Tania.
Título: Del nuevo producto biológico para el cáncer al impacto en la salud poblacional / From the new biologic cancer drug to the impact in population health
Fonte: Rev. cuba. salud pública;38(supl.5):781-793, 2012.
Idioma: es.
Resumo: La investigación clínica no termina con el registro del nuevo medicamento, sino con la modificación de los indicadores de salud poblacional. Este artículo ilustra la experiencia de la biotecnología cubana en el propósito de contribuir a la reducción de la mortalidad por tumores malignos. En el control del cáncer, la biotecnología tiene cuatro espacios de impacto: el primero es en la prevención primaria mediante vacunas profilácticas, el segundo, consiste en las técnicas de diagnóstico precoz, el tercero es la estratificación de los pacientes mediante marcadores moleculares pronósticos o predictivos y el cuarto rol radica en el tratamiento de la enfermedad diseminada con vacunas terapéuticas y anticuerpos monoclonales que reconocen blancos específicos en los tumores. El uso de estas terapias ha traído consigo un cambio de paradigma del tratamiento del cáncer. La experiencia cubana ha sido exitosa debido a la existencia de un sistema de salud con altos estándares basado en la cobertura completa y equidad de acceso, el desarrollo del nivel primario de atención médica, centro de gravedad del sistema cubano y el desarrollo en las últimas tres décadas de una industria biotecnológica nacional, innovadora y con capacidad productiva para cubrir las necesidades nacionales de productos y exportar. A pesar de los avances, quedan grandes retos técnicos y metodológicos. La investigación científica posregistro permitirá trazar la estrategia para optimizar el impacto de los nuevos productos en la salud poblacional, encaminada a incrementar la esperanza de vida de los cubanos

The clinical research does not finish with the registration of a new drug, but with the modification of the population health indexes. This paper set forth the experience of the Cuban biotechnology in cancer control, in order to achieve the reduction of mortality rate from malignant tumors. Biotechnology has four areas of remarkable impact in cancer control: first, the primary prevention by means of prophylactic vaccines; second, the techniques for early diagnosis; third, the stratification of patients according to the molecular prognostic or predictive biomarkers and fourth, the treatment of advanced disseminated cancer with therapeutic cancer vaccines and monoclonal antibodies that detect specific targets in tumors. The use of these therapies has entailed a shift of paradigm in the cancer therapy. The Cuban experience has been successful due to the existence of a high standard health system based on complete coverage and equal access, the development of the primary medical care- the core of the Cuban health system -and the advance of a national, innovative biotech industry with manufacturing capacity to meet the national demand and to export products. In spite of the advances, big technical and methodological challenges still remain. Post-registration scientific research would define the strategy to optimize the impact of the new products in the population's health, aimed at increasing the life expectancy of the Cuban people
Descritores: Anticorpos Monoclonais/uso terapêutico
Biotecnologia
Vacinas Anticâncer
Neoplasias/terapia
Responsável: CU1.1 - Biblioteca Médica Nacional



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde